“we remain optimistic with the collaborative relationships we have with our states that over the course of the year that this gap will continue to narrow.”

In context

“state renewals through April and if we're still on track to close that rate acuity gap by the end of the year. Andrew Witty : Thanks so much for the question. I'm going to ask Krista to answer that for you. Krista Nelson : Yeah, thanks for the question. We were encouraged with the progress that we made on rates in the second half of 2024, which really continued into our 1/1 rate cycle. And as John and Andrew both mentioned, overall the gap between acuity of the population and the rate funding is really narrowing with each cycle as well as through some off cycle adjustments that we have seen. We have -- it's really too early to call the rates on 7/1, but about 35% of our revenue renews in that 7/1 cycle. And with each cycle that base data continues to reflect more recent experience. And so we remain optimistic with the collaborative relationships we have with our states that over the course of the year that this gap will continue to narrow. Operator: And our next question comes from Lance Wilkes with Bernstein. Lance Wilkes: Great, thanks. Could you talk a little bit about the first quarter MLR impacts and maybe breaking out the impacts that were driven by the premium increases that you described and maybe any sort of deductible increases? But also were there impacts as a result of the way in which you're approaching prior authorization, any changes in that? And then do you have a sense as to maybe increased follow through from your house calls and primary care actions as far as getting follow-up visits tied to risk adjustment activity? And lastly, were there any one time good guys in the first quarter, which perhaps supported medical loss ratio and caused the distinction between 1Q versus guidance? Andrew Witty: Thanks so m”